Clinical trials: Myelodysplastic Syndrome (MDS)
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases
RATIONALE: Pemetrexed disodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Studying samples of cerebrospinal fluid and blood from patients with cancer in the laboratory may help…
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT00424242
- Testing
- Pemetrexed
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Northwestern University
Acute Myelogenous Leukemia, Graft Versus Host Disease
Sirolimus With Tacrolimus for Graft-vs-Host Disease Prophylaxis After Un-Related Stem Cell Transplantation
The purpose of this study is to evaluate the ability of sirolimus to prevent graft versus host disease (GVHD) in patients following stem cell transplant from an unrelated donor.
- Conditions
- Acute Myelogenous Leukemia, Graft Versus Host Disease, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia
- Trial name
- NCT00144677
- Testing
- sirolimus, tacrolimus
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Dana-Farber Cancer Institute
Acute Myeloid Leukemia, Myelodysplastic Syndromes
Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation
The purpose of this study is to evaluate whether addition of a low dose of total body irradiation (TBI) to a standard preparation for transplant [total lymphoid irradiation (TLI) and anti-thymocyte globulin (ATG)] conditioning…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder, Chronic Lymphocytic Leukemia
- Trial name
- NCT03734601
- Testing
- Total body irradiation (TBI), Anti-thymocyte globulin (ATG), Tacrolimus
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Stanford University
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Graft-Versus-Host Disease Prophylaxis in Treating Patients With Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
This randomized phase III trial studies how well graft-vs-host disease (GVHD) prophylaxis works in treating patients with hematologic malignancies undergoing unrelated donor peripheral blood stem cell transplant.
- Conditions
- Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
- Trial name
- NCT01231412
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Fludarabine Phosphate
- Where
- 11 sites in United States, Denmark and 1 more
- Volunteers
- 174 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
The goal of this clinical research study is to learn if the combination of clofarabine, idarubicin, and cytarabine, or the combination of fludarabine, idarubicin, and cytarabine can help control Acute myeloid leukemia (AML) and…
- Trial name
- NCT01289457
- Testing
- Clofarabine, Idarubicin, Cytarabine
- Where
- United States
- Volunteers
- 282 people
- Sponsor
- M.D. Anderson Cancer Center
Myeloid Malignancies, Acute Myelogenous Leukemia
Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation
This is a single institution study of fludarabine and busulfan versus fludarabine, busulfan and low dose total body irradiation in patients undergoing allogeneic stem cell transplantation.
- Conditions
- Myeloid Malignancies, Acute Myelogenous Leukemia, Chronic Myelogenous Leukemia, Myeloproliferative Disorders
- Trial name
- FLUBUTBI (NCT01366612)
- Testing
- Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose), Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Hackensack Meridian Health
Acute Myeloid Leukemia, Myelodysplastic Neoplasm
Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement
This study is a multicenter, single-arm, prospective phase II clinical trial that evaluates the efficacy and safety of an intensive conditioning regimen with thiotepa combined with busulfan, fludarabine, and cytarabine for…
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Neoplasm, Chronic Myelomonocytic Leukemia, Myeloid Sarcoma
- Trial name
- NCT06111612
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Melanoma, Myelodysplastic Syndrome
SCRI Tissue Testing Registry
Sarah Cannon Research Institute (SCRI) is committed to improvement and excellence in clinical research and correlative science. To this end, the SCRI Oncology Research Consortium will collect written consent from patients…
- Conditions
- Melanoma, Myelodysplastic Syndrome, Multiple Myeloma, Lymphoma
- Trial name
- NCT00965861
- Testing
- Tissue Registry Study
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- SCRI Development Innovations, LLC
Myelodysplastic Syndromes, Myeloproliferative Neoplasm
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
The purpose of the study is to see if participants with anemia due to their type of MDS or MDS/MPN will experience a more decreased need for regular blood transfusions if they take luspatercept plus best supportive care, and what…
- Conditions
- Myelodysplastic Syndromes, Myeloproliferative Neoplasm, Anemia
- Trial name
- NCT05732961
- Testing
- Luspatercept
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission
Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications
RATIONALE: A personalized Internet-based program may help improve fatigue, depression, and quality of life in long-term survivors of stem cell transplant.
- Conditions
- Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Trial name
- NCT00799461
- Testing
- internet-based intervention, questionnaire administration, psychosocial assessment and care
- Where
- United States
- Volunteers
- 1,337 people
- Sponsor
- Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Myelodysplastic Syndromes, Hematopoietic Cell Transplant
Study of Quality of Life in Older vs. Younger Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndromes
This is a multi-center, Phase II, cross-sectional study comparing quality of life (QOL) as assessed by patient-reported outcomes (PROs) in older (≥65 years) adults vs younger (55-64 years) undergoing allogeneic hematopoietic cell…
- Trial name
- NCT03558386
- Testing
- ePRO survey
- Where
- 6 sites in United States
- Volunteers
- 92 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Acute Myeloid Leukemia, Myelodysplastic Syndrome
A Study of Bomedemstat (IMG-7289/MK-3543) With and Without ATRA, in Participants With Advanced Myeloid Malignancies (IMG-7289-CTP-101/MK-3543-001)
This is an open label study of the dose and duration of an orally administered lysine-specific demethylase 1 (LSD1) inhibitor, bomedemstat, in patients with high-risk acute myeloid leukemia (AML) and high-risk myelodysplastic…
- Trial name
- NCT02842827
- Testing
- bomedemstat, tretinoin
- Where
- Australia
- Volunteers
- 45 people
- Sponsor
- Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Myelofibrosis, Myeloid Metaplasia
A Study of Gleevec in Patients With Idiopathic Myelofibrosis or Chronic Myelomonocytic Leukemia (CMML)
The purpose of this study is to determine the effects (good and bad) of Gleevec in patients with BCR-negative myeloproliferative disorders including myelofibrosis with myeloid metaplasia and chronic myelomonocytic leukemia.
- Conditions
- Myelofibrosis, Myeloid Metaplasia, Agnogenic Myeloid Metaplasia, Chronic Myelomonocytic Leukemia
- Trial name
- NCT00136409
- Testing
- Imatinib mesylate
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Dana-Farber Cancer Institute
Myelodysplastic Syndromes, Acute Myeloid Leukemia
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome
patients with MDS (Myelodysplastic Syndrome) and mutated IDH1 patients will be treated with AG120 (IDH1 inhibitor)
- Trial name
- NCT03503409
- Testing
- AG-120
- Where
- 38 sites in France, Italy
- Volunteers
- 68 people
- Sponsor
- Groupe Francophone des Myelodysplasies
Paroxysmal Nocturnal Hemoglobinuria
A Study of Efficacy and Safety of FXS6837 in Anti-C5 Treated PNH Patients.
This is an single arm, open label designed phase III study to evaluate the efficacy and safety of oral FXS6837 capsules in PNH patients with residual anemia despite the stable treatment with anti-C5 antibody.
- Trial name
- NCT07914894
- Testing
- FXS6837 Capsule
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Primary Myelofibrosis, Myelodysplastic Syndromes
Connect® Myeloid Disease Registry
The purpose of the Connect® Myeloid disease registry is to provide unique insights into treatment decisions and treatment patterns as they relate to clinical outcomes of patients with myeloid diseases in routine clinical…
- Conditions
- Primary Myelofibrosis, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
- Trial name
- NCT01688011
- Testing
- Luspatercept
- Where
- 158 sites in United States, Puerto Rico
- Volunteers
- 2,013 people
- Sponsor
- Celgene
Acute Myeloid Leukemia, Chronic Myeloid Leukemia
Phase I/II Study of Immune Therapy After Allograft in Patients With Myeloid Hemopathy
Patients with acute or chronic myeloid leukemia, or myelodysplastic syndrome, underwent allogeneic stem cell transplantation from HLA-identical donor (related or unrelated) after reduced-intensity conditioning regimen.
- Conditions
- Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Myelodysplastic Syndrome
- Trial name
- ALLO-WT1 (NCT01819558)
- Testing
- recwt1-A10+AS01B
- Where
- France
- Volunteers
- 2 people
- Sponsor
- Institut Paoli-Calmettes
Myelodysplastic Syndromes
The Efficacy and Safety of Lenalidomide Monotherapy in Red Blood Cell Transfusion Dependent Subjects With Myelodysplastic Syndrome (MDS) Associated With Del (5q) Abnormality
The purpose of this study is to evaluate the efficacy of lenalidomide treatments to achieve haematopoietic improvement in subjects with low- or intermediate-1 risk International Prognostic Scoring System1 (IPSS) myelodysplastic…
- Trial name
- NCT00874978
- Testing
- lenalidomide
- Where
- United Kingdom
- Volunteers
- 36 people
- Sponsor
- King's College Hospital NHS Trust
Myelodysplastic Syndromes
Pre-emptive Therapy With DEC-C to Improve Outcomes in MDS Patients With Measurable Residual Disease Post Allogeneic Hematopoietic Cell Transplant
The investigators hypothesize that early measurable residual disease (MRD)-guided pre-emptive therapy with decitabine + cedazaridine (DEC-C) will decrease the risk of progression in post-transplant myelodysplastic syndromes (MDS)…
- Trial name
- NCT04742634
- Testing
- DEC-C, MyeloSeq-HD
- Where
- United States
- Volunteers
- 209 people
- Sponsor
- Washington University School of Medicine
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).
The purpose of the study is to determine the maximal tolerated dose and schedule of CC-486, known as oral azacitidine, in patients with AML or MDS after allogeneic hematopoetic stem cell transplant (HSCT).
- Trial name
- NCT01835587
- Testing
- CC-486
- Where
- 5 sites in United States, United Kingdom
- Volunteers
- 31 people
- Sponsor
- Celgene
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.